Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 20-valent conjugate vaccine (Pfizer)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pneumococcal 20-valent conjugate vaccine (PCV20), marketed under the brand names Prevnar 20 and Prevenar 20 (formerly Apexxnar), is an active immunizing agent developed by Pfizer. It is a sterile suspension containing purified capsular polysaccharides from 20 distinct serotypes of *Streptococcus pneumoniae* (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F). Each polysaccharide is individually conjugated to a non-toxic diphtheria CRM197 carrier protein to enhance immunogenicity via T-cell dependent pathways. PCV20 is approved for the prevention of invasive pneumococcal disease, pneumonia, and acute otitis media in pediatric and adult populations. In clinical trials, PCV20 is frequently utilized as an active comparator (such as in 'Stage 2' infant cohorts) to evaluate the safety and immunogenicity of next-generation pneumococcal vaccine candidates.
- Brand names
- ApexxnarPrevenar 20Prevenar20Prevenar-20Prevnar 20Prevnar20Prevnar-20
- Other names
- 20-valent pneumococcal conjugate vaccine20vPnCPCV20PCV-20PCV 20PCV20 (Stage 2)pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)
02
Targets
NeuraminidaseCPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on pneumococcal 20-valent conjugate vaccine (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 20-valent conjugate vaccine (Pfizer).